Unicycive Therapeutics (UNCY)
(Delayed Data from NSDQ)
$4.15 USD
-0.06 (-1.43%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.14 -0.01 (-0.24%) 6:28 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
UNCY 4.15 -0.06(-1.43%)
Will UNCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for UNCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UNCY
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
UNCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for UNCY
Unicycive Therapeutics (UNCY) Publishes Promising Trial Data on CKD Treatment | UNCY Stock News
Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data ...
Unicycive Therapeutics announces publication of OLC trial data
Unicycive Therapeutics: Manageable CMC Speed Bump - Pill Burden Edge Intact, Buying
Unicycive Therapeutics: Manageable CMC Speed-Bump--Pill-Burden Edge Intact, Buying